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Abstract—The aim of this work is to estimate the medication 
adherence of patients with heart failure through the 
application of a data mining approach on a dataset including 
information from saliva and breath biomarkers.  The 
method consists of two stages.  In the first stage, a model for 
the estimation of adherence risk of a patient, exploiting 
anamnestic and instrumental data, is applied.  In the second 
stage, the output of the model, accompanied with data from 
saliva and breath biomarkers, is given as input to a 
classification model for determining if the patient is 
adherent, in terms of medication.  The method is evaluated 
on a dataset of 29 patients and the achieved accuracy is 96%. 
Keywords-medication adherence; saliva biomarkers; 
breath biomarkers; data mining; heart failure 
I.  INTRODUCTION 
Heart failure (HF) is a common diagnosed chronic 
disease among individuals 65 year and older.  It is 
characterized by recurrent hospitalizations, high mortality, 
poor quality of life and increased healthcare costs.  A 
variety of reasons contribute to the high prevalence of this 
disease.  Non-adherence of HF patients to treatment 
suggestions (suggestions regarding medication, nutrition 
and physical activity exercising) has been proven a 
significant contributor to the presence of HF adverse 
events (destabilizations, re-hospitalizations, mortality) [1-
4]. 
Direct and indirect methods have been implemented 
for the estimation of medication adherence, with the 
Medication Event Monitoring System (MEMS) and 
measurement of drug levels in blood and urine to be the 
golden standard of indirect and direct methods, 
respectively [5].  Estimation of medication adherence has 
also gained the interest of researchers who performed 
studies in order to identify the modifiable factors 
associated with medication adherence and developed 
models for predicting adherence in adults with HF.  The 
prediction models reported in the literature exploit 
information concerning sociodemographic characteristics 
of the patients, frequency of medication intake, medical 
condition, biological data and results of clinical 
examinations [3, 6-13].   
The last years’ studies have revealed the strong 
correlation of saliva and breath biomarkers with HF 
severity, progression and mortality through statistical 
analysis methods [14-28].  Furthermore, in [29] a 
computational method for the estimation of HF patient 
status, using saliva biomarkers, is presented. 
The current work, taking into account the valuable 
information that saliva and breath biomarkers carry 
regarding HF patient status and the dependence of HF 
patient status on treatment adherence, aims to examine and 
identify the potentially significant correlates of HF patient 
medication adherence to HF-related saliva and breath 
biomarkers.  In order this to be achieved a two stage model 
is built by employing data mining techniques and utilizing 
saliva and breath biomarkers data in combination with 
sociodemographic, medical and clinical information.  
More specifically, in the first stage, the estimation of 
adherence risk of HF patients in terms of medication and 
overall adherence (medication, nutrition and physical 
activity exercise) is applied, while in the second stage, the 
HF patient is classified as medication adherent or not by 
combining the output of the first stage with saliva 
biomarkers data, breath biomarkers data, New York Heart 
Association (NYHA) class and the status (acute, 
progressive, stable) of the HF patient.   
The NYHA class, and the status of the patient, at the 
current phase, are provided by the experts.  However, in 
the future they will be derived from the NYHA class 
detection module and Event Prediction Module, 
respectively, of the HEARTEN Knowledge Management 
System (KMS) developed within the HEARTEN project 
[30].   
The HEARTEN project [30] creates an mHealth 
ecosystem for empowering HF patients, optimizing 
disease management and improving patient adherence.  
The last is accomplished by two modules of the 
HEARTEN KMS, Adherence risk module and Treatment 
adherence module.  The main innovation of HEARTEN, 
from the clinical point of view, is the integration of 
different data deriving from a variety of sensors, as well as 
the development of non-invasive breath/saliva biosensors.  
The correlation of these different sensor/biosensor outputs 
has not previously been produced and the extraction of 
meaningful knowledge through an automated, quick and 
reliable process is currently lacking. 
II. MATERIALS AND METHODS 
A. Dataset 
The proposed method is evaluated using a dataset of 29 
patients collected by the clinical center of the Universita 
Di Pisa (UNIPI), Italy within the HEARTEN project [30].  
The dataset consists of patients: (i) diagnosed with HF 
(Framingham criteria) who have continuous symptoms 
with frequent recurrence, (ii) belonging to the functional 
NYHA I-IV class followed by an optimal treatment, (iii) 
who have been recently hospitalized, (at least one in the 
last six months), (iv) who have undergone one 
electrocardiogram (in the last 12 months ) and have HF 
symptoms.  Patients who are underage, with very severe 
HF, with obesity and advanced chronic kidney failure are 
not included. 
The features recorded for each patient can be grouped 
into the following categories: (i) General Information, (ii) 
Allergies, (iii) Medical Condition, (iv) Drugs, (v) 
Biological data related to HF disease, (vi) Clinical 
Examinations, (vii) Adherence, (viii) Biomarkers. Uric 
Acid, Tumor Necrosis Factor –a, Cortisol and 8-iso-
prostaglandin F2a, Isoprene and Acetone are measured.   
These features are recorded from the first time of 
patient’s hospitalization (Hosp) until discharge (Dis) every 
second day.  Thus, a set of 57 instances are collected (21 
instances at Dis phase and 8 instances at Hosp and Dis 
phase).  Each instance is characterized by the experts as 
high, medium, low adherent.  The dataset includes: 42 
instances characterized as high adherent and 15 instances 
characterized as medium adherent.  Taking into 
consideration that the patients are in the hospital, the case 
of low adherence is not included.  Since the aim of the 
study is estimation of medication adherence, a control 
group is not included. 
B. The proposed method 
The proposed method consists of two stages: i) 
estimation of adherence risk of the patient, ii) 
classification of the patient as medication adherent or not.  
A schematic representation of the proposed method is 
shown in Fig. 1 and a detailed description of each stage is 
provided below. 
Stage 1 – Estimation of adherence risk: Estimation of 
medication and overall adherence risk is performed.  The 
model presented in [13] is applied.  The model takes as 
input features belonging to groups (i)-(vii) (Section II-A) 
and applies feature selection and classification techniques 
(Fig. 2).  The Stage 1 gives two outputs.  The first output 
is, if the patient is medication adherent or not and the 
second, if the patient is overall adherent or not. 
 
Figure 1.  Flowchart of the proposed method. 
 
Figure 2.  Stage 1 of the proposed method. 
TABLE I: ABBREVIATIONS FOR THE TYPE OF INPUT OF STAGE 2 OF THE 
PROPOSED METHOD. 
Abbreviation Type of input 
A Demographic (Age, Gender) 
B NYHA class 
C Patient status 
D Blood biomarker (NT-proBNP)* 
E Saliva biomarkers (UA, TNF-a, 8-iso-F2a)* 
F Breath biomarkers (Isoprene, Acetone) 
G Medication adherence risk  
H Overall adherence risk 
* NT-proBNP: N-terminal pro b-type natriuretic peptide, UA: Uric 
Acid, TNF-a: Tumor Necrosis Factor-a, 8-iso-F2a: 8-iso-
prostaglandin F2a 
Stage 2- Classification: It takes as input the output of 
the Stage 1, as well as demographic information (gender 
and age), NYHA class of the patient, patient status (acute, 
progressive, stable), blood biomarkers (N-terminal pro b-
type natriuretic peptide), saliva biomarkers (Uric Acid, 
Tumor Necrosis Factor –a, Cortisol and 8-iso-
prostaglandin F2a) and breath biomarkers (Isoprene, 
Acetone).  An abbreviation is assigned to each of the 
above mentioned inputs (presented in Table I) that will be 
used throughout the rest of this paper. The number of 
instances (57) remains constant for all the datasets, while 
the number of features is differentiated depending on the 
type of input that is removed.  
For the classification nine classifiers are employed.  
Five of them belong to the category of tree-based 
classifiers (Random Forests-RF [31], Logistic Model 
Trees-LMT [32], J48 [33], Simple Classification and 
regression tree-CART [34], Rotation Forest-ROT [35]), 
two of them to the category of kernel-based classifiers 
(Radial Basis Function Network-RBF [36], Support 
Vector Machine-SVM [37]) and two of them to the 
category of Bayesian classifier (Bayesian Network-BN 
[38] and Naive Bayes-NB [39]).  The most representative 
classifiers from each category are selected. 
III. RESULTS 
The proposed method is applied for each of the 
datasets presented in Table II.  The difference between the 
datasets is the combination of features that compose each 
dataset.  The results of the proposed method in terms of 
accuracy, as well as the classifier that provides the best 
results are presented in Table III. 
In order to examine if the participation of medication 
adherence risk (G) affects the performance of the proposed 
method the type of input G is removed from the datasets 
and the experiments are repeated (Table IV).   
Taking into account that the characterization of patient 
status as acute, progressive and stable is annotated by the 
clinical experts without the utilization of an established 
scale, a fact that may introduce subjectivity to the datasets 
and influence the results of the proposed method, the 
specific feature (type of input C) is removed and the Stage 
2 of the proposed method is reapplied.  The results are 
presented in Table V. 
In addition, both types of input, C and G, are removed 
and the second stage of the proposed method is evaluated 
again.  Table VI presents the results. 
In order to examine the performance of the proposed 
method, when only the saliva or breath biomarkers are 
available two versions of the Dataset #1 are created.  The 
first version includes only saliva biomarkers, while the 
second includes only breath biomarkers.  The accuracy for 
the two cases is presented in Table VII. 
TABLE II: DESCRIPTION OF THE DATASET. 
Dataset A B C D E F G H 
#1        
#2        
#3        
#4        
#5        
#6        
#7        
#8         
Grey cells represent the type of input that is removed from each 
dataset 
TABLE III: RESULTS OF THE PROPOSED METHOD. 
Datasets 
#1 #2 #3 #4 #5 #6 #7 #8
Accuracy 
95% 91% 93% 91% 88% 89% 88% 86% 
Classifier 
RF BN ROT BN RF 
BN 
ROT 
LMT 
RF 
ROT ROT RF CART 
TABLE IV: RESULTS OF THE PROPOSED METHOD BY REMOVING TYPE OF 
INPUT G FROM THE DATASETS DESCRIBED IN TABLE II. 
Datasets 
#1 #2 #3 #4 #5 #6 #7 #8
Accuracy 
96% 89% 95% 93% 91% 89% 88% 86% 
Classifier 
ROT RF BN ROT 
ROT 
RF 
CART 
RF LMT RF RF CART 
TABLE V: RESULTS OF THE PROPOSED METHOD BY REMOVING TYPE OF 
INPUT C FROM THE DATASETS DESCRIBED IN TABLE II. 
Datasets 
#1 #2 #3 #4 #5 #6 #7 #8
Accuracy 
95% 91% 96% 95% 89% 86% 88% 86% 
Classifier 
BN 
ROT 
RF 
ROT RF RF 
RBF 
LMT 
RF 
RF RBF RF 
RF 
CART 
TABLE VI: RESULTS OF THE PROPOSED METHOD BY REMOVING TYPE OF 
INPUT C AND G FROM THE DATASETS DESCRIBED IN TABLE II. 
Datasets 
#1 #2 #3 #4 #5 #6 #7 #8
Accuracy 
96% 89% 95% 96% 89% 88% 86% 86% 
Classifier 
RF ROT BN LMT RF BN RBF 
RBF 
RF 
CART 
RF 
CART 
TABLE VII: RESULTS OF THE PROPOSED METHOD WHEN ONLY ONE TYPE 
OF BIOMARKER IS INCLUDED IN THE DATASET. 
Dataset Accuracy Classifier 
#1 with saliva biomarkers 95% ROT 
#1 with breath biomarkers 96% ROT 
IV. DISCUSSION 
An automated computational approach for the 
estimation of medication adherence of the HF patients is 
presented based on data expressing saliva and breath 
biomarkers, a feature that differentiate the proposed 
method from other methods reported in the literature.  The 
proposed method consists of two stages.  In the first stage, 
a model for the estimation of medication and overall 
adherence risk is applied, while in the second stage a 
classification model to classify a patient as medication 
adherent or not is built.  The proposed method is applied to 
eight datasets described in Table II.  The best results (95% 
accuracy) are obtained when all types of input (A to H) 
participate in the dataset and the RF classifier is applied.  
The results presented in Table III also indicate that the 
removal of information expressing NYHA class (Dataset 
#3) and the removal of blood biomarker NT-proBNP 
(Dataset #4) decrease slightly, 2% and 4% percent, 
respectively, the performance of the proposed method. 
Additionally, further experiments are presented to 
evaluate the performance of the proposed method and 
more specifically of the second stage of the method.  The 
difference between the experiments is the dataset that is 
given as input to the Stage 2.  More specifically, the 
removal of the type of input G from the datasets affects 
either positively or negatively (Table IV) the results of the 
proposed method.  The small differences (maximum 
increase 3%, maximum decrease 2%) in five out of eight 
cases, presented in Table III and Table IV, indicate that the 
contribution of medication adherence risk depends on the 
dataset and the classifier that is utilized. 
The contribution of C type of input can be estimated 
from the results presented in Table V.  The results indicate 
that the status of patient, as it is estimated by clinical 
experts, can contribute to the classification of patient as 
medication adherent or not when information regarding 
the NYHA class or NT-proBNP of the patient are not 
available.  This specific observation will be further 
validated in the future where the patient status will be 
provided automatically by the Event prediction module of 
the HEARTEN KMS through the application of a 
computational approach.  Some preliminary results 
presented in [29] show that the discrimination of acute 
versus non acute status can be achieved with 85% 
accuracy, while the discrimination of stable versus 
progressive status can be achieved with 69% accuracy. 
The utilization of breath and saliva biomarkers as the 
only input of the proposed method (Table V – Dataset #8) 
results to an estimation of medication adherence with 86% 
accuracy.  The presence in the dataset of only one type of 
biomarker results to 95 (using only saliva biomarkers) and 
96% (using only breath biomarkers) accuracy. 
The current study examines the predictive power of 
saliva and breath biomarkers toward medication adherence 
taking into consideration the fact that biomarkers 
significantly correlate with HF severity and progression 
and provide valuable information about the status of the 
patient, which strongly depends on the adherence of the 
patient to the experts’ treatment suggestions.  The results 
verify the existence of correlation between the biomarkers 
and adherence, however observations regarding which of 
the saliva and breath biomarkers are more indicative will 
be extracted in the future, when larger datasets will be 
available.  The results of the study can be used as a basis 
for the development of low cost, easy to use, non-invasive 
breath and saliva biosensors.  The communication of the 
biosensors with a mHealth application will facilitate the 
increase and improvement of the medication adherence. 
V. CONCLUSIONS 
It is widely accepted that existing medications for HF 
can provide great health benefits, if the treatment by the 
medical experts’ suggestions are followed. Specifically, 
HF symptoms, emergency department visits and 
hospitalizations can be reduced and survival can be 
increased. However, nowadays, medication adherence 
remains a challenge for patients with HF resulting not 
only in health-related adverse events but also in high 
healthcare costs. 
The current study addresses the problem of medication 
adherence of HF patients through the exploitation of saliva 
and breath biomarkers in combination with demographic 
information, NYHA class and status of the patient, blood 
biomarker and medication and overall adherence risk 
extracted by a model taking into consideration 
sociodemographic, medical and clinical information.   
It is expected that this method can be fully integrated 
and employed in a mHealth application allowing the 
estimation of the patient’s medication adherence on time, 
enabling in this way the provision of personalized advices 
and suggestions, which in turn will result in avoiding 
adverse events and improving the patient’s health status 
and overall quality of life. 
ACKNOWLEDGMENTS 
This work is supported by the HEARTEN project that has 
received funding from the European Union’s Horizon 2020 
research and innovation program under grant agreement No 
643694. 
REFERENCES 
[1] M. R. Cowie, “The heart failure epidemic,” Medicographia, 2012. 
[2] A. S. Desai and L. W. Stevenson, “Rehospitalization for heart 
failure: predict or prevent?,” Circulation, vol. 126, no. 4, pp. 501–
506, Jul. 2012. 
[3] B. Riegel and G. J. Knafl, “Electronically monitored medication 
adherence predicts hospitalization in heart failure patients,” Patient 
Prefer Adherence, vol. 8, pp. 1–13, Dec. 2013. 
[4] J.-R. Wu, D. K. Moser, T. A. Lennie, and P. V. Burkhart, 
“Medication adherence in patients who have heart failure: a review 
of the literature,” Nurs. Clin. North Am., vol. 43, no. 1, p. 133–
153; vii–viii, Mar. 2008. 
[5] K. C. Farmer, “Methods for measuring and monitoring medication 
regimen adherence in clinical trials and clinical practice,” Clin 
Ther, vol. 21, no. 6, p. 1074–1090; discussion 1073, Jun. 1999. 
[6] G. J. Knafl and B. Riegel, “What puts heart failure patients at risk 
for poor medication adherence?,” Patient Prefer Adherence, vol. 8, 
pp. 1007–1018, 2014. 
[7] A. M. Hajduk, S. C. Lemon, D. D. McManus, D. M. Lessard, J. H. 
Gurwitz, F. A. Spencer, R. J. Goldberg, and J. S. Saczynski, 
“Cognitive impairment and self-care in heart failure,” Clin 
Epidemiol, vol. 5, pp. 407–416, 2013. 
[8] T. Mathes, T. Jaschinski, and D. Pieper, “Adherence influencing 
factors – a systematic review of systematic reviews,” Arch Public 
Health, vol. 72, no. 1, Oct. 2014. 
[9] V. V. Dickson, G. J. Knafl, and B. Riegel, “Predictors of 
medication nonadherence differ among black and white patients 
with heart failure,” Res Nurs Health, vol. 38, no. 4, pp. 289–300, 
Aug. 2015. 
[10] B. Aggarwal, A. Pender, L. Mosca, and H. Mochari-Greenberger, 
“Factors associated with medication adherence among heart failure 
patients and their caregivers,” J Nurs Educ Pract, vol. 5, no. 3, pp. 
22–27, 2015. 
[11] D. T. Juarez, A. E. Williams, C. Chen, Y. G. Daida, S. K. Tanaka, 
C. M. Trinacty, and T. M. Vogt, “Factors affecting medication 
adherence trajectories for patients with heart failure,” Am J Manag 
Care, vol. 21, no. 3, pp. e197-205, Mar. 2015. 
[12] Y.-J. Son, H.-G. Kim, E.-H. Kim, S. Choi, and S.-K. Lee, 
“Application of support vector machine for prediction of 
medication adherence in heart failure patients,” Healthc Inform 
Res, vol. 16, no. 4, pp. 253–259, Dec. 2010. 
[13] G. S. Karanasiou, E. E. Tripoliti, T. G. Papadopoulos, F. G. 
Kalatzis, Y. Goletsis, K. K. Naka, A. Bechlioulis, A. Errachid and 
D. I. Fotiadis, “Predicting adherence of patients with heart failure 
through machine learning techniques”, Healthc Technol Lett., vol. 
3(3), pp.165-170, 2016. 
[14] W. Doehner and S. D. Anker, “Uric acid in chronic heart failure,” 
Semin. Nephrol., vol. 25, no. 1, pp. 61–66, Jan. 2005. 
[15] D. L. Mann, “Inflammatory Mediators and the Failing Heart,” 
Circulation Research, vol. 91, no. 11, pp. 988–998, Nov. 2002. 
[16] L. I. B. Sikkeland et al., “Increased Levels of Inflammatory 
Cytokines and Endothelin-1 in Alveolar Macrophages from 
Patients with Chronic Heart Failure,” PLOS ONE, vol. 7, no. 5, p. 
e36815, 2012. 
[17] H. K. Gaggin and J. L. Januzzi, “Biomarkers and diagnostics in 
heart failure,” Biochim. Biophys. Acta, vol. 1832, no. 12, pp. 
2442–2450, Dec. 2013. 
[18] N. Ansari, A. Hasan, and M. Owais, “A study of inflammatory 
markers and their correlation with severity, in patients with chronic 
heart failure.,” Biomedical Research, vol. 23, pp. 408–415, 2012. 
[19] A. Suska, U. Alehagen, I. Lundstrom, and U. Dahlstrom, “Salivary 
Alpha-Amylase Activity, a New Biomarker in Heart Failure?,” 
Journal of Clinical & Experimental Cardiology, Jun. 2012. 
[20] U. M. Nater and N. Rohleder, “Salivary alpha-amylase as a non-
invasive biomarker for the sympathetic nervous system: current 
state of research,” Psychoneuroendocrinology, vol. 34, no. 4, pp. 
486–496, May 2009. 
[21] M. Yamaji et al., “Serum cortisol as a useful predictor of cardiac 
events in patients with chronic heart failure: the impact of 
oxidative stress,” Circ Heart Fail, vol. 2, no. 6, pp. 608–615, Nov. 
2009. 
[22] D. B. Sawyer, “Oxidative Stress in Heart Failure: What are we 
missing?,” Am J Med Sci, vol. 342, no. 2, pp. 120–124, Aug. 2011. 
[23] K. Nakamura et al., “Beta-Blockers and Oxidative Stress in 
Patients with Heart Failure,” Pharmaceuticals (Basel), vol. 4, no. 8, 
pp. 1088–1100, Aug. 2011. 
[24] B. Phypers and J. T. Pierce, “Lactate physiology in health and 
disease,” Contin Educ Anaesth Crit Care Pain, vol. 6, no. 3, pp. 
128–132, Jun. 2006. 
[25] C. Lazzeri, S. Valente, M. Chiostri, and G. F. Gensini, “Clinical 
significance of lactate in acute cardiac patients,” World J Cardiol, 
vol. 7, no. 8, pp. 483–489, Aug. 2015. 
[26] T. Doenst, T. D. Nguyen, and E. D. Abel, “Cardiac Metabolism in 
Heart Failure - Implications beyond ATP production,” Circ Res, 
vol. 113, no. 6, pp. 709–724, Aug. 2013. 
[27] L. T. McGrath, R. Patrick, B. Silke, “Breath isoprene in patients 
with heart failure”, Eur J Heart Fail vol. 3, pp. 423-427, 2001. 
[28] F. G. Marcondes-Braga, I. G. Gutz, G. L. Batista, P. H. Saldiva, S. 
M. Ayub-Ferreira, et al., “Exhaled acetone as a new biomaker of 
heart failure severity”, Chest vol. 142, pp.  457-466, 2012. 
[29] E. E. Tripoliti, T. G. Papadopoulos, G. S. Karanasiou, F. G. 
Kalatzis, Y. Goletsis, S. Ghimenti, T. Lomonaco, F. Bellagambi, 
M. G. Trivella, R. Fuoco, M. Marzilli, M. C. Scali, A. Errachid, D. 
I. Fotiadis, “A Computational Approach for the Estimation of 
Heart Failure Patients Status Using Saliva Biomarkers”, submitted 
to 39th Annual International Conference of the IEEE Engineering 
in Medicine and Biology Society, July 207, Korea. 
[30] “HEARTEN: A co-operative mHealth environment targeting 
adherence and management of patients suffering from Heart Fail-
ure.” Available: http://www.hearten.eu/. 
[31] L. Breiman, “Random Forests,” Machine Learning, 1997, vol. 45. 
[32] N. Landwehr, M. Hall, and E. Frank, “Logistic Model Trees,” 
Machine Learning, 2005. 
[33] S. L. Salzberg, “C4.5: Programs for Machine Learning by J. Ross 
Quinlan. Morgan Kaufmann Publishers, Inc., 1993,” Mach Learn, 
vol. 16, no. 3, pp. 235–240, Sep. 1994. 
[34] L. Breiman, J. H. Friedman, R. A. Olshcn, and C. J. Stone, 
“Classification and Regression Trees. Wadsworth International 
Group, Belmont CA,” Wadsworth International Group, Belmont, 
California., vol. 1, Jan. 1984. 
[35] J. J. Rodríguez, L. I. Kuncheva, and C. J. Alonso, “Rotation forest: 
A new classifier ensemble method,” IEEE Trans Pattern Anal 
Mach Intell, vol. 28, no. 10, pp. 1619–1630, Oct. 2006. 
[36] J. Cristianini and Shawe-Taylor, “An Introduction to Support 
Vector Machines and Other Kernel-based Learning Methods,  
Pattern Recognition and Machine Learning,” USA, Cambridge 
University Press, 2000. 
[37] E. Frank, “Fully Supervised Training of Gaussian Radial Basis 
Function Networks in WEKA.” [Online]. Available: 
http://www.cs.waikato.ac.nz/~ml/publications/2014/rbf_networks_
in_weka_description.pdf. [Accessed: 05-May-2016]. 
[38] K. P. Murphy, “Dynamic bayesian networks: representation, 
inference and learning,” PhD dissertation, University of California, 
Berkeley, Citeseer, 2002. 
[39] T. Mitchell, “Machine Learning,” in McGraw-Hill 
Science/Engineering/Math, 1997. 
